Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 34 of 34 publications.
Skip to main content
Karve SJ, Price GL, Davis KL, Pohl G, Walgren RA. Health care utilization and associated costs in elderly persons with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):4273. doi: 10.1182/blood.V120.21.4273.4273
Cohen C, Davis KL, Meyers JL. Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. Poster presented at the 11th International Congress on Drug Therapy in HIV Infection; November 2012.
Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.
Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Assessing impacts of major depressive disorder on depression. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 1, 2012. Berlin, Germany.
Davis AE, Mehrotra S, Friedewald J. Improving utilization and outcomes of high kidney donor profile index kidney transplants. Poster presented at the Annual Meeting ofthe Institute for Operations Research and Management Science; October 2012. Previously presented at the 2010 American Transplant Congress.
Cilenti D, Wells R, Kum HC, Domino M, Goyal RK, Hillemeier M. How NC maternal and child health services and outcomes changed during a period of revenue cuts. Poster presented at the NC Public Health Association Conference; September 2012.
Ferguson JE3rd, Goyal RK, Raynor MC, Nielsen ME, Pruthi RS, Brown PM, Wallen EM. Cost analysis of robot-assisted laparoscopic versus hand-assisted laparoscopic partial nephrectomy. J Endourol. 2012 Aug;26(8):1030-7.
Nastaoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor M, Friedberg J, Link B, Cerhan J, Dawson K, Flowers C. Characteristics and effectiveness of rituximab (R) maintenance regimens among US patients diagnosed with follicular lymphoma (FL) 2004-2007. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(s1):95-6. Previously presented at the 53rd Annual Meeting of the American Society of Hematology.
Mauskopf JA, Candrilli SD, Chevrou-Severac H, Ochoa JB. Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. World J Surg Oncol. 2012 Jul 1;10:136.
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.
Gnanasakthy A, Lewis SA, Clark MJ, Mordin MM, Evans E, DeMuro-Mercon CJ. The impact of primary endpoints on patient-reported outcome label claims. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012.
Mladsi DM, Graham JB, Ronquest NA. Trade-off analysis: an extension of threshold pricing analysis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A169.
Mladsi D, Herring WL, Earnshaw S. Cost-effectiveness analysis in personalized medicine: general hypotheses and corresponding decision tree structures for screening, diagnostic, predictive, prognostic, surveillance, and monitoring tests. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A168-9.
Karve SJ, Price G, Davis KL, Pohl G, Smith EN. Comparison of treatment patterns, health care utilization, and direct costs in elderly patients with distant-stage small cell lung cancer (SCLC) versus non-small cell lung cancer (NSCLC) using the SEER-medicare database. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 2012.
Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early parkinson disease therapies. Am J Manag Care. 2012 May 1;4(3):99-107.
Mladsi D, Curtis S, Bell MJ, Ito T, Wilson M, Aboud M. Resource utilisation and cost of managing adverse events (AEs) associated with highly active antiretroviral therapy (HAART) in patients with HIV-1. Poster presented at the 18th Annual Conference of the British HIV Association; April 1, 2012. Birmingham, UK. [abstract] HIV Med. 2012 Apr 18; 13(SI):17-8.
Cohen C, Davis KL, Meyers JL. Effect of daily antiretroviral pill burden on hospitalizations in United States medicaid enrollees with HIV: an analysis of hospital characteristics and costs. Poster presented at the 24th Annual Meeting of the Academy of Managed Care Pharmacy; April 2012.
Davis AE, Mehrotra S, Friedewald J. Improving utilization and outcomes of high kidney donor profile index kidney transplants. Poster presented at the 2012 American Transplant Congress; April 2012.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D. Costs of illness due to endemic cholera. Epidemiol Infect. 2012 Mar 1;140(03):500-9.
Auzinger G, Playford G, Graham CN, Narula H, Charbonneau C, Weinstein D. Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia. Poster presented at the International Symposium of Intensive Care and Emergency Medicine; March 2012.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Kauf TL, Davis KL, Earnshaw SR, Davis EA. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012 Feb 1;6:155-64.
Zimovetz EA, Wolowacz SE, Classi PM, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012 Feb 1;10(1):1.
Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012 Jan 1;15(1):166-74.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012 Jan 1;15(1):55-64.
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Yen L, Davis KL, Hodgkins P, Loftus EVJr, Erder MH. Direct medical costs of diverticulitis in a US managed care population. Am J Manag Care. 2012;4(5):e118-29.
Alwin J, Brodtkorb T. Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2012;13(1):25-31.
Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ. 2012;15(2):219-24. doi: 10.3111/13696998.2011.638954
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.